ANTEV LTD

HQ - London

Summary

Antev is a clinical stage biotech developing Teverelix as first in market product for high CV risk prostate cancer patients & patients with first Acute Urinary Retention (AUR) episode due to enlarged prostate.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 53 M

Avg. Deal Size£ 53 M

Market Context

Senior Management

Amit Kohli
CEO